
Please try another search
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Xiaobin Wu | 62 | 2021 | Independent Non-Executive Director |
Xiaodong Wang | 61 | 2021 | Non-Executive Director |
Jeffrey S. Farrow | 62 | 2021 | Independent Non-Executive Director |
Joshua G. Liang | 31 | 2020 | CEO & Executive Director |
Xiang Liao | 58 | 2021 | Independent Non-Executive Director |
Ralf Leo Clemens | 71 | 2022 | Non-Executive Director |
Donna Marie Ambrosino | 72 | 2022 | Non-Executive Director |
Peng Liang | 63 | 2018 | Founder, Chief Scientific Officer & Chairman of the Board |
Thomas Edward Leggett | 47 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review